Русский
Method for measurement of the size of the HIV cell reservoir and for its determination in patients who are not experienced with ART
DOI: https://dx.doi.org/10.18565/epidem.2021.11.4.66-72
Kvasov N.A., Polyakova A.K., Lopatukhin A.E., Murzakova A.V., Shemshura A.B., Kireev D.E.
1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) Cinical Center for AIDS Prevention and Control, Ministry of Health of the Krasnodar Territory, Krasnodar, Russia
Materials and methods. Examinations were made in 268 HIV-infected patients with no ART experience with known dates of infection. At the time of blood sampling, VL and the immune status index were determined in patients. DNA was isolated from peripheral blood mononuclear cells (PBMC) and quantified by real-time PCR. The size of the reservoir was calculated as the number of copies of the proviral DNA to the total number of cells. Results are expressed as log10 copies/106 PBMC.
Results. HIV DNA concentration ranged from 0.04 to 3.84 log10 HIV DNA copies/106 PBMC (median 2.22, interquartile range 1.74–2.72 log10 HIV DNA copies/106 PBMC). The teservoir size correlated with VL (r = 0.526; p < 0.01), immune status (r = -0.189; p < 0.05) and duration of infection (r = -0.282; p < 0.01).
Conclusion. The concentration of HIV DNA as a marker of the size of the viral reservoir provides additional information about the course of the disease. It can be recommended to use this indicator in conjunction with VL and immune status for early infections.
Literature
1. Deeks S.G., Lewin S.R., Havlir D.V. The end of AIDS: HIV infection as a chronic disease. The Lancet 2013; 382(9903), 1525–33. https://doi.org/ 10.1016/S0140-6736(13)61809-7 2. Турсунов Р.А., Канестри В.Г., Симонова Е.Г., Раичич Р.Р. Антиретровирусная терапия-новая эпоха профилактики ВИЧ-инфекции. ВИЧ-инфекция и иммуносупрессии 2018; 10(1): 37–46. https://doi.org/10.22328/2077-9828-2018-10-1-37-46 Tursunov R.A., Kanestri V.G., Simonova E.G., Raichich R.R. [Antiretrovirus therapy - a new epoch of prevention of HIV infection. HIV]. Infection and Immunosuppressive Disorders 2018; 10(1): 37–46. (In Russ.). https://doi.org/10.22328/2077-9828-2018-10-1-37-46 3. Barton K., Winckelmann A., Palmer S. HIV-1 reservoirs during suppressive therapy. Trends in Microbiology 2016; 24(5), 345–55. https://doi.org/10.1016/j.tim.2016.01.006 4. Abdel-Mohsen M., Richman D., Siliciano R.F., Nussenzweig M.C., Howell B.J., Martinez-Picado J., Montaner L.J. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine 2020; 26(9): 1339–50. https://doi.org/10.1038/s41591-020-1022-1 5. Kiselinova M., De Spiegelaere W., Buzon M.J., Malatinkova E., Lichterfeld M., Vandekerckhove L. Integrated and total HIV-1 DNA predict ex vivo viral outgrowth. PLoS Рathogens 2016; 12(3); e1005472. https://doi.org/10.1371/journal.ppat.1005472 6. Tsiara C.G., Nikolopoulos G.K., Bagos P. G., Goujard C., Katzenstein T.L., Minga A.K., Hatzakis A. Impact of HIV type 1 DNA levels on spontaneous disease progression: a meta-analysis. AIDS Research and Human Retroviruses 2012; 28(4): 366–73. https://doi.org/10.1089/aid. 2011.0032 7. Shiramizu B., Paul R., Williams A., Shikuma C., Watters M., Grove J., Valcour V. HIV proviral DNA associated with decreased neuropsychological function. J. Neuropsychiatry Clin. Neurosci. 2007; 19(2): 157–63. https://doi.org/10.1176/jnp.2007.19.2.157 8. Parisi S.G., Andreis S., Mengoli C., Scaggiante R., Ferretto R., Manfrin V., Sarmati L. Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy. J. Clin. Microbiol. 2012; 50(2): 258–63. https://doi.org/10.1128/JCM. 06022-11 9. Rouzioux C., Hubert J.B., Burgard M., Deveau C., Goujard C., Bary M., Meyer L. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J. Infectious Diseases 2005; 192(1), 46–55. https://doi.org/10.1086/430610 10. Бобкова М.Р. Стратегии излечения ВИЧ-инфекции: основные методологические подходы и проблемы их реализации. ВИЧ-инфекция и иммуносупрессии 2020; 12(1): 22–31. https://doi.org/10.22328/2077-9828-2020-12-1-22-31 Bobkova M.R. [HIV infection cure strategies: basic methodological approaches and difficulties of their implementation]. HIV Infection and Immunosuppressive Disorders 2020; 12(1): 22–31. (In Russ.) https://doi.org/10.22328/2077-9828-2020-12-1-22-31 11. Wong J. K., Hezareh M., Günthard H. F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278(5341): 1291–5. https://doi.org/10.1126/science.278.5341.1291 12. Butler S.L., Hansen M.S., Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nature Medicine 2001; 7(5): 631–4. https://doi.org/10.1038/87979 13. Bruner K.M., Wang Z., Simonetti F.R., Bender A.M., Kwon K.J., Sengupta S., Siliciano R.F. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 2019: 566(7742): 120–5. https://doi.org/10.1038/s41586-019-0898-8 14. Gaebler C., Lorenzi J.C., Oliveira T.Y., Nogueira L., Ramos V., Lu C. L., Nussenzweig M.C. Quadruplex qPCR for qualitative and quantitative analysis of the HIV-1 latent reservoir. bioRxiv 2019; 641951. https://doi.org/10.1101/641951 15. Веселова Е.И., Каминский Г.Д., Самойлова А.Г., Васильева И.А. (2019). Резервуар ВИЧ у больных ВИЧ-инфекцией. Туберкулез и болезни легких 2019; 97(5): 50–7. https://doi.org/10.21292/2075-1230-2019-97-5-50-57 Veselova E.I., Kaminsky G.D., Samoylova A.G., Vasilyeva I.A. HIV reservoir in HIV patients. Tuberculosis and Lung Diseases 2019; 97(5): 50–7. (In Russ.). https://doi.org/10.21292/2075-1230-2019-97-5-50-57 16. Rouzioux C., Avettand-Fenoël V. Total HIV DNA: a global marker of HIV persistence. Retrovirology 2018; 15(1): 1–7. https://doi.org/ 10.1186/s12977-018-0412-7 17. Wang Z., Simonetti F.R., Siliciano R.F., Laird G.M. Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir. Retrovirology 2018; 15(1): 1–9. https://doi.org/10.1186/s12977-018-0404-7 18. Imamichi H., Dewar R.L., Adelsberger J.W., Rehm C.A., O’Doherty U., Paxinos E., Lane H.C. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proceedings of the National Academy of Sciences 2016; 113(31): 8783–8. https://doi.org/10.1073/pnas.1609057113 19. Pham H.T., Mesplède T. The latest evidence for possible HIV-1 curative strategies. Drugs in Context 2018; (7). DOI: 10.7573/dic.212522 20. Sengupta S., Siliciano R.F. Targeting the latent reservoir for HIV-1. Immunity 2018; 48(5): 872–95. https://doi.org/10.1016/j.immuni. 2018.04.030 21. Saitoh A., Hsia K., Fenton T., Powell C.A., Christopherson C., Fletcher C.V., Spector S.A. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J. Infect. Dis. 2002; 185(10): 1409–16. https://doi.org/10.1086/340614 22. Hoen B., Cooper D.A., Lampe F.C., Perrin L., Clumeck N., Phillips A. N., QUEST Study Group. Predictors of virological outcome and safety in primary HIV type 1–infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin. Infect. Dis. 2007; 45(3): 381–90. https://doi.org/10.1086/519428 23. Ngo-Giang-Huong N., Deveau C., Da Silva I., Pellegrin I., Venet A., Harzic M., French PRIMO Cohort Study Group. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15(6): 665–73. 24. Tsiara C.G., Nikolopoulos G.K., Bagos P. G., Goujard C., Katzenstein T.L., Minga A.K., Hatzakis A. Impact of HIV type 1 DNA levels on spontaneous disease progression: a meta-analysis. AIDS Research and Human Retroviruses 2012; 28(4): 366–73. https://doi.org/10.1089/aid. 2011.0032 25. Goujard C., Bonarek M., Meyer L., Bonnet F., Chaix M.L., Deveau C., Agence Nationale de Recherche sur le Sida PRIMO Study Group. CD4+ cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin. Infect. Dis. 2006; 42(5): 709–15. https://doi.org/10.1086/500213
About the Autors
Nikita A. Kvasov, Junior Researcher, Central Research Institute of Epidemiology, Federal Center of Hygiene and Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being,Moscow, Russia; kvasov.bio@gmail.com; https://orcid.org/0000-0001-7153-8615
Angelina K. Polyakova, Junior Researcher, Central Research Institute of Epidemiology, Federal Center of Hygiene and Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; angelina.polya@gmail.com; https://orcid.org/0000-0001-8763-2331
Alexey E. Lopatukhin, Researcher, Central Research Institute of Epidemiology, Federal Center of Hygiene and Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being,Moscow, Russia; a.lopatukhin@gmail.com; https://orcid.org/0000-0002-2826-699X
Anastasia V. Murzakova, Researcher, Central Research Institute of Epidemiology, Federal Center of Hygiene and Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Moscow, Russia; murzakova_a.v@mail.ru; https://orcid.org/0000-0002-1390-8021
Andrey B. Shemshura, Cand. Med. Sci., Clinical Laboratory Diagnostician, Clinical Centre for AIDS Control, Ministry of Health of the Krasnodar Region, Krasnodar, Russia; shemsh@mail.ru; https://orcid.org/0000-0003-1637-4229
Dmitry E. Kireev, Cand. Biol. Sci., Head, Researcher Group, Central Research Institute of Epidemiology, Federal Center of Hygiene and Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; dmitkireev@yandex.ru; https://orcid.org/0000-0002-7896-2379
Similar Articles
